Why is Johnson & Johnson paying $5.5 billion over baby powder lawsuits? – Firstpost

Johnson & Johnson (J&J) has agreed to pay an estimated $5.5 billion to resolve the overwhelming majority of lawsuits alleging that its talc-based baby powder and other talc products caused ovarian cancer, marking what could be the final chapter in one of the largest and longest-running product liability battles in United States corporate history.

The proposed agreement, announced on July 27, covers approximately 76,000 existing claims pending in US federal and state courts, representing nearly all of the remaining ovarian cancer-related talc litigation against the healthcare giant.

Although Johnson & Johnson continues to deny that its talc products are unsafe or contain asbestos, it says the agreement is intended to end years of costly litigation and allow the company to focus on its core healthcare business.

However, the settlement will only become legally binding if 95 per cent of eligible ovarian cancer claimants in state and federal courts agree to participate.

What does the $5.5 billion settlement include?

Instead of continuing to fight thousands of individual lawsuits — or attempting to resolve the claims through bankruptcy proceedings — the company has negotiated a direct out-of-court agreement with plaintiffs’ lawyers.

Under the framework, Johnson & Johnson expects to pay approximately $3 billion in 2027, with the remaining payments scheduled for 2028. While the company estimates the settlement at $5.5 billion, the final amount could exceed $7 billion, depending on the number of qualifying claimants who participate.

According to attorney Chris Seeger, who represents around 2,500 talc claimants and helped negotiate the settlement, the agreement assigns specific values to eligible ovarian cancer cases but does not place a cap on Johnson & Johnson’s overall financial obligation if more qualifying claims are included.

Unlike the company’s previous bankruptcy proposals, the agreement applies only to existing lawsuits and does not attempt to resolve future claims.

That distinction proved significant during negotiations. By excluding future cases, more money becomes immediately available for current claimants, while compensation is expected to be distributed within 18 months rather than over a period exceeding a decade.

Plaintiffs’ law firms described the agreement as a fair outcome after years of litigation. “We got a fair settlement, and our clients are going to be happy with it,” Seeger said.

Why was Johnson & Johnson sued over baby powder?

The litigation stems from allegations that Johnson & Johnson’s talc-based products — including its once-iconic baby powder — caused ovarian cancer in women who regularly used the powder for feminine hygiene.

Talc is a naturally occurring mineral composed primarily of magnesium, silicon, oxygen and hydrogen. It has long been used in cosmetics because of its ability to absorb moisture and reduce friction.

The lawsuits argued that talc deposits can naturally occur alongside asbestos, a known carcinogen, and alleged that microscopic talc particles — and, in some cases, asbestos fibres — entered the reproductive system through genital application, eventually contributing to ovarian cancer.

The litigation eventually evolved into two broad categories. One involved mesothelioma, with plaintiffs alleging exposure to asbestos-contaminated talc caused cancers affecting the lining of the lungs or abdomen. Many of those claims have already been resolved through separate settlements or individual trials.

The second and much larger group consisted of ovarian cancer lawsuits, in which women argued that prolonged use of talc-based powder contributed to the development of cancer.

Johnson & Johnson has consistently rejected both allegations. The company maintains that decades of scientific research show cosmetic talc is safe and that its products never contained asbestos.

It also points to numerous epidemiological studies that, according to the company, found no statistically significant association between cosmetic talc use and ovarian cancer.

Plaintiffs, meanwhile, argued that internal company documents dating back to the 1950s and 1970s showed executives and scientists were aware that some raw talc from mines in Vermont and Italy occasionally contained trace amounts of asbestos minerals such as tremolite and actinolite.

They also alleged that Johnson & Johnson failed to adequately disclose those concerns and continued marketing the products for decades.

How did years of courtroom battles lead to the settlement?

Before pursuing bankruptcy, Johnson & Johnson experienced mixed results in talc litigation. While it won several individual trials and successfully reduced or overturned some verdicts on appeal, it also faced enormous jury awards.

Among the most significant was the 2018 Missouri case, in which 22 women claimed talc products caused ovarian cancer. A jury initially awarded $4.69 billion, later reduced to $2.1 billion after appeals.

Other recent verdicts also demonstrated the uncertainty surrounding the litigation. In 2025, a Baltimore jury awarded $1.5 billion in a mesothelioma case,
while another Los Angeles case resulted in a $966 million award, although the punitive damages portion was later struck down.

Separate ovarian cancer cases produced both substantial awards and comparatively modest verdicts, highlighting the wide variation in jury decisions across different jurisdictions.

Johnson & Johnson also achieved several important legal victories. The company prevailed in numerous individual trials, successfully challenged plaintiffs’ expert witnesses, and secured rulings disqualifying some plaintiffs’ lawyers from participating in litigation.

Most recently, a federal judge cast doubt on whether individual plaintiffs could reliably prove that talc specifically caused their ovarian cancer, a decision viewed as another significant legal win for the company.

Johnson & Johnson said those courtroom successes strengthened its legal position, but ultimately chose settlement to eliminate ongoing uncertainty.

“While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” said Erik Haas, Johnson & Johnson’s Vice President of Litigation.

What was the failed ‘Texas Two-Step’ bankruptcy strategy?

For more than three years, Johnson & Johnson attempted to resolve the lawsuits through a controversial legal strategy commonly known as the “Texas Two-Step.”

Beginning in 2021, the company created subsidiaries — including LTL Management and later Red River Talc LLC — to absorb its talc-related liabilities before placing those entities into Chapter 11 bankruptcy.

The approach was designed to halt thousands of lawsuits through an automatic litigation stay while pursuing a global settlement under bankruptcy court supervision.

However, each attempt ultimately failed.

The first bankruptcy filing by LTL Management was dismissed in 2023 after the US Third Circuit Court of Appeals concluded the subsidiary was not in genuine financial distress because Johnson & Johnson remained financially strong and had committed funding support.

A second bankruptcy filing by LTL Management met the same fate later that year.

The company’s third effort, involving Red River Talc LLC and an $8.2 billion proposed settlement,
was dismissed in 2025 by a federal bankruptcy judge in Houston, who ruled that bankruptcy was not the appropriate venue for a solvent corporation seeking to resolve mass tort litigation.

Following those rulings, the litigation resumed in March 2025, exposing Johnson & Johnson once again to thousands of individual trials. The collapse of the bankruptcy strategy ultimately pushed both sides toward direct negotiations that resulted in the current settlement.

What happens next?

In 2020, the company stopped selling talc-based baby powder in the United States and Canada, citing declining demand driven by what it described as misinformation surrounding product safety.

It later transitioned its global baby powder business entirely to a cornstarch-based formulation.

In 2023, Johnson & Johnson also spun off its consumer health division into Kenvue. Under the separation agreement, Johnson & Johnson retained responsibility for talc-related lawsuits in the United States and Canada, while Kenvue assumed responsibility for certain claims outside North America.

Financially, analysts view the settlement as substantial but manageable for Johnson & Johnson, given its strong balance sheet and cash generation.

By spreading payments across 2027 and 2028, the company aims to preserve liquidity while continuing investments in pharmaceuticals, medical technology and research.

The agreement also establishes an important legal precedent. After repeated court rejections of its bankruptcy strategy, Johnson & Johnson has returned to a traditional negotiated settlement, highlighting the challenges large corporations may face when attempting to use Chapter 11 proceedings to resolve mass product liability claims.

If the required 95 per cent claimant approval is secured, the settlement would bring to a close a legal battle that has lasted more than 15 years and involved tens of thousands of lawsuits.

Also Watch:

With inputs from agencies